ACRS241220P5000
- 1.35
- 0.000.00%
Aclaris Therapeutics Newsroom
Cantor Fitzgerald Upgrades Aclaris Therapeutics(ACRS.US) to Buy Rating
Aclaris Therapeutics Price Target Raised to $7.00/Share From $2.00 by Leerink Partners
Aclaris Therapeutics Raised to Outperform From Market Perform by Leerink Partners
A Quick Look at Today's Ratings for Aclaris Therapeutics(ACRS.US), With a Forecast Between $3 to $13
Jefferies Upgrades Aclaris Therapeutics to Buy, Price Target Is $7
Promising Potential of Aclaris Therapeutics' BSI-045B and Pipeline Elevates Buy Rating
Piper Sandler: Authorized trade is transformative. Target price for Aclaris (ACRS.US) is significantly raised to $13.
Aclaris Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS), McKesson (MCK) and Enhabit, Inc (EHAB)
Aclaris Therapeutics: Hold Rating Amid Mixed Trial Outcomes and Strategic Uncertainties
Stifel Maintains Aclaris Therapeutics(ACRS.US) With Hold Rating, Raises Target Price to $3
Stifel Nicolaus Sticks to Its Hold Rating for Aclaris Therapeutics (ACRS)
BTIG Maintains Aclaris Therapeutics(ACRS.US) With Hold Rating
H.C. Wainwright Maintains Aclaris Therapeutics(ACRS.US) With Hold Rating
Aclaris Therapeutics Analyst Ratings
H.C. Wainwright Reaffirms Their Hold Rating on Aclaris Therapeutics (ACRS)
H.C. Wainwright Maintains Aclaris Therapeutics(ACRS.US) With Hold Rating
Aclaris Therapeutics: Hold Rating Amidst Clinical Uncertainty and Strategic Review
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS), Celcuity (CELC) and Intuitive Surgical (ISRG)
H.C. Wainwright Maintains Aclaris Therapeutics(ACRS.US) With Hold Rating